title: The state of the art in non-small cell lung cancer immunotherapy.
abstract: Once considered an ineffective modality in lung cancer, immunotherapy has emerged as one of the most promising therapeutic strategies for this lethal disease. The past few years have seen a plethora of clinical trials evaluating various immunotherapeutic approaches in lung cancer. This article discusses the current status of immunotherapy in non-small cell lung cancer with a review of completed studies and ongoing trials.
authors: Division of Hematology and Medical Oncology, New York University School of Medicine, New York, New York.. Electronic address: Nagashree.seetharamu@nyumc.org.
authors: Nagashree
authors: N
authors: Seetharamu
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines
keywords: CTLA-4; PD-1/PD-L1; immunotherapy; lung cancer vaccines; non–small cell lung cancer